MicrobiotiX
IT Mirae Tower, 33 Digital-ro 9-gil, Geumcheon-gu, Seoul, Seoul-t'ukpyolsi, 08511, South Korea
Overview
MicrobiotiX develops bacteriophage-based therapeutics targeting diseases caused by multidrug-resistant bacteria. The company’s platform includes a phage library panel targeting multidrug-resistant bacteria, an in silico module, and a cGMP-grade phage manufacturing facility. Led by CEO Dongeun Yong, MicrobiotiX plans to use its latest funding to expand operations and accelerate R&D. The company raised KRW 20 billion in a Series B announced September 3, 2025. This round follows a KRW 15 billion Series B investment secured in October 2024. Backers for the latest round were not disclosed.
- Total raised
- $14M
- Funding rounds
- 1
- Latest round
- Series B
- Latest activity
- Sep 2025
Industries
- Biotechnology
- Health Care
- Life Science
- Therapeutics
Recent funding
Series B
Sep 2025
$14M
Team
No current team members are available.